Spyre Therapeutics's total assets for Q2 2025 were $538.83M, a decrease of -5.43% from the previous quarter. SYRE total liabilities were $83.06M for the fiscal quarter, a -4.71% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.